Background
Thousands of claimants have brought a group action in the United Kingdom against Johnson & Johnson (J&J) and its affiliates. They allege that their use of the company’s talc-based Baby Powder, which they claim was contaminated with asbestos and other harmful substances, caused them to develop malignant mesothelioma or ovarian cancer. The claims, proceeding under a Group Litigation Order (GLO), are for damages in negligence and deceit.
This judgment arises from a case management conference to address several procedural matters. A key issue was that the claimants’ legal team had narrowed the scope of the ovarian cancer claims to only “high-grade serous” ovarian cancer. This meant that over 1,000 of the original claimants no longer met the Standard Minimum Requirements (SMRs) to be part of the GLO. In response, J&J filed an application to strike out those claims.
The parties also asked the court to decide on the structure of the litigation going forward. They agreed in principle on a staged approach but disputed which “common issues” should be decided in the first phase of the trial.
The Court’s Holding
Mrs Justice Hill DBE denied the defendants’ application to strike out the claims of the numerous individuals who no longer qualified for the GLO. While describing the situation as “deeply lamentable,” the court found that the claimants’ solicitors had not committed an abuse of process. Rather than imposing the “draconian remedy” of a strike-out, which could strip the claimants of cost protections, the court ordered a closely managed process for the claimants’ solicitors to formally file for discontinuance of those claims over the coming months.
The court approved a staged approach for the litigation, ordering a “Stage 1” trial to be held in early 2028. This initial trial will be confined to two overarching issues: Contamination and Generic Causation. The Contamination issue will determine what the Baby Powder was made of, whether it was contaminated with asbestos and/or heavy metals, and the adequacy of J&J’s historical testing. The Generic Causation issue will determine whether the substances found in the powder are scientifically capable of causing mesothelioma and high-grade serous ovarian cancer.
However, the court rejected the claimants’ request to also include the issue of J&J’s Knowledge (i.e., what the company knew or should have known about the contamination) in the Stage 1 trial. The judge reasoned that determining knowledge would require a much wider factual inquiry, add significant time and cost to the initial trial, and undermine the goal of expediency. The issues of contamination and generic causation are potentially dispositive of the entire case, making them the most efficient issues to try first.
Key Takeaways
- In large-scale group litigation, UK courts may favor a managed discontinuance process over striking out claims, even when a significant portion of the claimant group is found not to meet the action’s criteria after filing.
- A staged trial approach is a key tool for managing complex product liability cases, allowing courts to resolve foundational scientific issues (like contamination and general causation) before proceeding to company knowledge or individual claims.
- The court defined the first critical battleground in the UK talc litigation: a trial focused on whether J&J’s Baby Powder contained asbestos and whether that substance is capable of causing the alleged cancers, deferring questions of what J&J knew for a later date.
Why It Matters
This judgment establishes the procedural roadmap for the massive talc litigation against Johnson & Johnson in the United Kingdom. By ordering a phased trial focusing first on the core scientific questions of contamination and causation, the court has created a pivotal, make-or-break moment for the litigation. The outcome of this first trial, set for 2028, will either be dispositive of the claims in J&J’s favor or validate the claimants’ core allegations, paving the way for thousands of claims to move forward.
The decision provides a clear example of the English judiciary’s pragmatic approach to managing complex, multi-claimant litigation. It balances the need for an efficient and expedited process—particularly given that many claimants are terminally ill—against the immense scope and complexity of the evidence. The ruling on the staged trial ensures that the most fundamental issues are resolved first, creating a framework that will likely have significant financial and legal consequences for both sides.